TCGA-KU-A66S-01A-21R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.092694064
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.290
- SPERMATOGENESIS+0.290
- MYC_TARGETS_V2+0.230
- DNA_REPAIR+0.220
- WNT_BETA_CATENIN_SIGNALING+0.100
- BILE_ACID_METABOLISM+0.090
- E2F_TARGETS-0.020
- FATTY_ACID_METABOLISM-0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.540
- INTERFERON_GAMMA_RESPONSE-0.510
- INFLAMMATORY_RESPONSE-0.490
- TNFA_SIGNALING_VIA_NFKB-0.460
- APICAL_SURFACE-0.440
- HYPOXIA-0.420
- UV_RESPONSE_DN-0.420
- APICAL_JUNCTION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 264656b8-d45c-4f5c-a431-366c566296fe | — | — | 0.932 |
| 2 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.901 |
| 3 | SRR5088853 | — | — | 0.891 |
| 4 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.890 |
| 5 | df6771b0-4b6c-4565-a2f1-4d919f8d68c9 | — | — | 0.887 |
| 6 | SRR4296068 | — | cohortA1 | 0.886 |
| 7 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.873 |
| 8 | R16 | — | — | 0.872 |
| 9 | BS_V9HVBBDW | medulloblastoma | — | 0.871 |
| 10 | MNG887 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |